GeoVax Labs (GOVX) Income from Continuing Operations (2010 - 2026)
GeoVax Labs (GOVX) posted quarterly Income from Continuing Operations of 4764745.0 for Q2 2026, up 11.27% year-over-year from 4282244.89 in Q2 2025, and down 7.84% quarter-over-quarter from 4418423.0 in Q4 2025.
GeoVax Labs (GOVX) Income from Continuing Operations (2010 - 2026) Analysis & Trends
GeoVax Labs (GOVX) has reported Income from Continuing Operations for 17 consecutive years, with 4764745.0 the latest figure, recorded in Q2 2026.
- In Q2 2026, Income from Continuing Operations rose 11.27% year-over-year to 4764745.0; the TTM figure through Jun 2026 stood at 21154076.0 (up 14.72% YoY), while the FY2025 annual figure was 64365656.0, down 4.23% from the prior year.
- Income from Continuing Operations fell to 4764745.0 in Q2 2026 per GOVX's latest filing, from 4418423.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 2241699.0 in Q2 2022 and bottomed at 8408818.0 in Q3 2023.
- Historically, Income from Continuing Operations has averaged 5381877.06 across 5 years, with a median of 5369783.0 in 2025.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations jumped 60.83% — and 2023, when it plunged 164.43%.
- GeoVax Labs' Income from Continuing Operations stood at 5383809.0 in 2022, then plunged by 41.02% to 7592408.0 in 2023, then dropped by 8.83% to 8262654.0 in 2024, then surged by 46.53% to 4418423.0 in 2025, then dropped by 7.84% to 4764745.0 in 2026.
- Business Quant data shows GOVX's Income from Continuing Operations at 4764745.0 in Q2 2026, 4418423.0 in Q4 2025, and 6601125.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | GeoVax Labs | 2.88 Mn | -260,493.75 | - | -4.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.76 Mn |
| Dec 31, 2025 | -4.42 Mn |
| Sep 30, 2025 | -6.60 Mn |
| Jun 30, 2025 | -5.37 Mn |
| Mar 31, 2025 | -5.36 Mn |
| Dec 31, 2024 | -8.26 Mn |
| Sep 30, 2024 | -5.82 Mn |
| Jun 30, 2024 | -5.06 Mn |
| Mar 31, 2024 | -5.85 Mn |
| Dec 31, 2023 | -7.59 Mn |
| Sep 30, 2023 | -8.41 Mn |
| Jun 30, 2023 | -5.93 Mn |
| Mar 31, 2023 | -4.04 Mn |
| Dec 31, 2022 | -5.38 Mn |
| Sep 30, 2022 | -3.97 Mn |
| Jun 30, 2022 | -2.24 Mn |
| Mar 31, 2022 | -2.43 Mn |
| Dec 31, 2021 | -13.74 Mn |
| Sep 30, 2021 | -1.95 Mn |
| Jun 30, 2021 | -1.49 Mn |